This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

This study has been completed.
Information provided by (Responsible Party):
Sokbom Kang, National Cancer Center, Korea Identifier:
First received: January 31, 2007
Last updated: April 25, 2012
Last verified: April 2012
-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix

Condition Intervention Phase
Cervical Cancer Drug: Belotecan(CKD-602) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

Further study details as provided by Sokbom Kang, National Cancer Center, Korea:

Primary Outcome Measures:
  • overall response rate of belotecan (CKD-602) [ Time Frame: 1 week before the start of Cycle 4, 3 weeks later Cycle 6 or at discontinuation of study treatment, and then at least every 3 months ]

Enrollment: 16
Study Start Date: January 2007
Study Completion Date: October 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CKD-602 Drug: Belotecan(CKD-602)
Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Other Name: Camptobel

Detailed Description:
  • list item one, to evaluate toxicities of Belotecan
  • list item two, to evaluate duration of primary response for responding patients
  • list item three, to evaluate time to disease progression
  • list item four, to evaluate progression free survival and overall survival.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, patients with recurrent uterine cervical carcinoma who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.
  • One of the following histologic types
  • Squamous cell carcinoma
  • Adenocarcinoma
  • Adenosquamous carcinoma
  • Clinically measurable disease
  • Performance status of 0, 1, 2 on the ECOG criteria

Exclusion Criteria:

  • Histology of neuroendocrine tumors
  • Patient previously treated with topoisomerase-I inhibitor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00430144

Korea, Republic of
National cancer center
Seoul, Korea, Republic of
Sponsors and Collaborators
Sokbom Kang
Principal Investigator: Sokbom Kang National cancer cencer
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sokbom Kang, director, gynecologic oncology research branch, National Cancer Center, Korea Identifier: NCT00430144     History of Changes
Other Study ID Numbers: NCCCTS-06-214
Study First Received: January 31, 2007
Last Updated: April 25, 2012

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic processed this record on August 17, 2017